NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Silence Therapeutics PLC SLN
4 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$559,000
▼ 98.7% vs FY2024
EPS · FY25
$-0.63
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-90.3%
Net margin · FY25
-15851.9%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 559,000.00
Revenue, FY2025 · full 4-year series below
Revenue
Net income
The company lost 15852 cents on every revenue dollar this year.
Per share
USD -0.63
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-90.3%
Return on equity, FY2025
ROE
Operating margin-16292.8%
Net margin-15851.9%
Return on assets-53.0%
Each USD of equity lost 90 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−70.4%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.14B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 131.4M
total assets, end of FY2025
Total assetsUSD 131.4M
EquityUSD 62.3M
CashUSD 11.3M
Current ratio8.72×
Equity funds 47% of total assets.
History
4 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
Revenue $B
0.0
0.0
0.0
0.0
Operating income $B
−0.1
−0.1
−0.1
−0.1
EBITDA $B
−0.1
−0.1
−0.1
−0.1
Income tax $B
0.0
0.0
0.0
0.0
Net income $B
−0.1
−0.0
−0.1
−0.1
EPS, diluted $
−0.63
−0.33
−0.49
−0.52
Dividend / sh $
·
·
·
·
Payout %
·
·
·
·
ROE %
−90.3
−58.1
−220.4
−184.9
Shares out B
0.14
0.14
0.12
0.11
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
14 of 14
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed